Steven Schmitt, PA
Medical · Atlanta, GANPI 1295849644
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $9,403 of the $15,418 with a category attached, or 61.0%. 27 manufacturers reported payments, led by Gilead at 37.4% of the total. Among medical clinicians in GA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 429 payments — averaging $35.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$6K
- Merck$3K
- Viiv Healthcare Company$3K
- AbbVie$483
- Theratechnologies Inc.$405
- Johnson & Johnson$391
- plus $3K from 21 others
What the payments were for
- Consulting fees$2,57817%
- Speaking & faculty fees$710%
- Travel & lodging$3,30121%
- Food & beverage$9,40361%
- Education$650%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 101 | $5,761 |
| Merck | 43 | $2,839 |
| Viiv Healthcare Company | 92 | $2,726 |
| AbbVie | 27 | $483 |
| Theratechnologies Inc. | 18 | $405 |
| Johnson & Johnson | 23 | $391 |
| Astellas Pharma US Inc | 14 | $339 |
| La Jolla Pharmaceutical Company | 14 | $321 |
| Napo Pharmaceuticals Inc | 17 | $320 |
| Paratek Pharmaceuticals, Inc. | 14 | $274 |
| Melinta Therapeutics, LLC | 10 | $273 |
| Ferring Pharmaceuticals Inc. | 10 | $197 |
| Shionogi Inc | 7 | $187 |
| Insmed, Inc. | 6 | $176 |
| Cumberland Pharmaceuticals, Inc. | 8 | $168 |
| Pfizer | 7 | $164 |
| Aimmune Therapeutics, Inc. | 5 | $128 |
| CSL Behring | 2 | $50 |
| Cormedix Inc. | 2 | $38 |
| Janssen Scientific Affairs, LLC | 2 | $37 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $34 |
| Hologic Sales And Service, LLC | 1 | $24 |
| GSK | 1 | $23 |
| Dynavax Technologies Corporation | 1 | $20 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $16 |
| Hydrofera LLC | 1 | $13 |
| Mayne Pharma Commercial LLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Biktarvy$2,834
How this compares
$15,418 in reported general payments places this provider in the 95th percentile of 950 medical providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 322 | $1,330,662 |
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 111 | $494,676 |
| TriumeqAbacavir/Dolutegravir/Lamivudi | 50 | $245,718 |
| SymtuzaDarunavir/Cob/Emtri/Tenof Alaf | 19 | $157,891 |
| TivicayDolutegravir Sodium | 43 | $102,589 |
| Egrifta SvTesamorelin Acetate | 13 | $88,219 |
| DescovyEmtricitabine/Tenofov Alafenam | 40 | $86,695 |
| PifeltroDoravirine | 35 | $75,817 |
| PrezistaDarunavir | 28 | $67,976 |
| OdefseyEmtricitab/Rilpiviri/Tenof Ala | 16 | $58,551 |
| JulucaDolutegravir/Rilpivirine | 11 | $44,046 |
| IsentressRaltegravir Potassium | 12 | $23,962 |
| Etravirine | 12 | $14,816 |
| Darunavir | 17 | $11,262 |
| ValacyclovirValacyclovir Hcl | 25 | $1,379 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy, Genvoya, Descovy | $5,761 | $1,912,033473 claims |
| Viiv Healthcare CompanyTriumeq, Tivicay, Juluca | $2,726 | $392,354104 claims |
| MerckPifeltro, Isentress | $2,839 | $99,77947 claims |
| Theratechnologies Inc.Egrifta Sv | $405 | $88,21913 claims |
| Janssen Scientific Affairs, LLCPrezista | $37 | $67,97628 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 950 medical providers in Georgia.
Other medical in Atlanta
- Kimberly OrleckAtlanta$727K
- Danna Dennis-CalderAtlanta$87K
- Ferrina ShethAtlanta$49K
- Adriana RuizAtlanta$39K
- Punam PunjaAtlanta$31K
- Adrienne AndersonAtlanta$25K
- Jeremiah RobinsonAtlanta$23K
- Taylor WeintraubAtlanta$15K
- Margaret SellersAtlanta$11K
- Katherine QuinleyAtlanta$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.